Clinical trials: FLU
Transplantation, Influenza Vaccines
Adjuvanted Influenza Vaccine in Stem Cell Transplant
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for transplant patients, studies have shown that…
- Trial name
- NCT02560909
- Testing
- FLUAD® influenza vaccine, FLUVIRAL®
- Volunteers
- 73 people
- Sponsor
- University Health Network, Toronto
Influenza
Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza
A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating…
- Trial name
- NCT01227798
- Testing
- Interferon alfacon-1
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Influenza
Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs
Background: The flu is a very infectious and contagious virus that affects both people and pigs. Studies show that pigs can be sources of the flu virus in humans.
- Trial name
- NCT02124096
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Flu
Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome
The aim of this study is to evaluate the efficacy and safety of a fixed combination of paracetamol, phenylephrine and chlorpheniramine in symptomatic treatment of common cold and flu-like illness in adults in a randomized…
- Trial name
- NCT01389518
- Testing
- Active
- Volunteers
- 146 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Inactivated Influenza Vaccine
Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age
Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age.
- Trial name
- GRC28 (NCT00242424)
- Testing
- 2005-2006 trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Influenza
A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.
This study will evaluate the efficacy and safety of Tamiflu in patients with clinically-diagnosed influenza occurring during an influenza outbreak within the community.
- Trial name
- NCT00436124
- Testing
- oseltamivir [Tamiflu]
- Where
- Italy
- Sponsor
- Hoffmann-La Roche
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00953524
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
- Where
- 15 sites in United States
- Volunteers
- 849 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Tract Infection
Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors
Seniors are a population vulnerable to respiratory infections. It is hypothesized that regular use of COLD-fX following an influenza vaccination would potentially augment immune response in the elderly.
- Trial name
- NCT00240461
- Testing
- COLD-fX natural health product, COLD-fX
- Where
- 5 sites in Canada, Netherlands
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Capital Health, Canada
Influenza Vaccine Response
Effect of Oral Supplements for Influenza Vaccine Response
The aim of this clinical trial is to explore the efficacy of fatty acid and bile acid based supplements on enhancing influenza vaccine immune response in adults aged 60-70 years. The objectives of this study are: 1.
- Trial name
- EOSIIVE-RCT (NCT06827873)
- Testing
- ARA (Arachidonic Acid) Supplementation, TUDCA (Tauroursodeoxycholic Acid) Supplementation, Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tsinghua University
Influenza, SARS-CoV-2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65…
- Trial name
- NCT06508320
- Testing
- mRNA-1083
- Where
- 17 sites in United States, Canada
- Volunteers
- 931 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study
The purpose of this study is to determine whether Chinese medicinal herbs are effective and safe for treating novel influenza A (H1N1) infection.
- Trial name
- NCT00935194
- Testing
- oseltamivir, blank, chinese medicinal herbs
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Capital Medical University
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
To perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live…
- Trial name
- CAIVT (NCT00192322)
- Testing
- CAIV-T 10^7, CAIVT 10^5, TIV
- Where
- 2 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
An open-label, dose-ranging influenza challenge study in healthy adult volunteers to determine the optimal infection dose and safety of a recombinant H3N2 (A/Texas/ A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain.
- Trial name
- NCT04978454
- Testing
- Influenza RG-A/Texas/71/2017 (H3N2) Challenge
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Influenza
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance…
- Trial name
- NCT01138397
- Testing
- Influenza virus vaccine (split virion, inactivated)
- Where
- 2 sites in Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Influenza Vaccine in Pediatric Transplant Subjects
The purpose of this study is to evaluate how well children responds to the recommended trivalent subviron influenza vaccine (flu shot).
- Trial name
- NCT00133510
- Testing
- Trivalent Subviron Influenza vaccine (Fluzone)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Influenza Vaccine in Lung Transplant Patients
This 5-year study was designed to investigate how antibody and T cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals.
- Trial name
- NCT00205270
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Haemophilus Influenzae Infection, Vaccines
Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b
Trial purpose is to evaluate the safety, tolerability and reactogenicity of the Vaccine for the prevention of infections caused by Haemophilus Influenzae Type b in volunteers aged 18-50.
- Trial name
- NCT05401305
- Testing
- Vaccine for the prevention of infections caused by Haemophilus influenza type b
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Influenza
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.
- Trial name
- NCT02612922
- Testing
- Nitazoxanide
- Where
- 28 sites in United States, Australia and 1 more
- Volunteers
- 325 people
- Sponsor
- Romark Laboratories L.C.
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02914275
- Testing
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Where
- 39 sites in United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Seqirus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.